Protocol summary

Study aim
1. Determining and comparing the mean of CRP, ESR, WBC, RBC, Albumin, Hb, ALT, AST, Arterial oxygen saturation and Lung CT scan result in the intervention and control groups in patients with Covid-19.
Design
clinical trial with control group with parallel groups, triple blind, on 80 patients, randomised with block randomization.
Settings and conduct
80 hospitalized and eligible patients in shaheed Beheshti Hospital in Qom which their PCR test is positive) based on their file number and randomized included in to this clinical trial.
Participants/Inclusion and exclusion criteria
Inclusion criteria: Patients Hospitalized in shaheed Beheshti Hospital in Qom with Covid-19 (their PCR test is positive). Patients between 18-65 years. Satisfaction of people to test this drug and its possible side effects.Exclusion criteria: History of allergy to plants of asteraceae. bile duct and intestinal obstruction. GI diseases,Diabetes and kidney failure. Alcohol consumption history Pregnant and lactating women and Married women who are in childbearing age and do not use reliable contraception method. Weight below 50 kg.Consumers of Lithium, digoxin, corticosteroids, niacin / nicotinic acid, metronidazole, disulfiram, tetracycline and fluoroquinolone antibiotics, hypoglycemic drugs, antiplatelet drugs, diuretics, Antacids. Consumers of s bloodroot, cat’s claw, chamomile, chaparral, chasteberry, damiana, Echinacea angustifolia, goldenseal, grapefruit juice, licorice, oregano, redclover,St.John’swort, wildcherry, andyucca.
Intervention groups
Intervention group: Dandelion capsule, 300 mg 3 times a day (900 mg), for 40 days. Control group: placebo capsule, 300 mg 3 times a day (900 mg), for 40 days.
Main outcome variables
CRP؛ ESR؛ WBC؛ RBC؛ Albumin؛ Hb؛ ALT؛ AST؛ Arterial oxygen saturation؛ Lung CT scan

General information

Reason for update
Acronym
IRCT registration information
IRCT registration number: IRCT20180513039641N2
Registration date: 2020-07-27, 1399/05/06
Registration timing: registered_while_recruiting

Last update: 2020-07-27, 1399/05/06
Update count: 0
Registration date
2020-07-27, 1399/05/06
Registrant information
Name
Hoda Abolhasani
Name of organization / entity
Country
Iran (Islamic Republic of)
Phone
+98 25 3320 9071
Email address
habolhasani@muq.ac.ir
Recruitment status
recruiting
Funding source
Expected recruitment start date
2020-07-26, 1399/05/05
Expected recruitment end date
2021-03-19, 1399/12/29
Actual recruitment start date
empty
Actual recruitment end date
empty
Trial completion date
empty
Scientific title
Determination of dandelion herbal capsule (Dandelherb) efficacy on symptom of patient with Covid-19 virus: a clinical trial study
Public title
Determination of dandelion capsule on patient with Covid-19 virus
Purpose
Treatment
Inclusion/Exclusion criteria
Inclusion criteria:
Patients Hospitalized in shaheed Beheshti Hospital in Qom with Covid-19 (their PCR test is positive). Patients between 18-65 years. Satisfaction of people to test this drug and its possible side effects.
Exclusion criteria:
History of allergy to plants of asteraceae. bile duct and intestinal obstruction. acute cholecystitis, empyema, acute gall bladder inflammation. Gastrointestinal diseases, gastritis, irritable bowel syndrome. Diabetes and kidney failure. Alcohol consumption history (more than 10 grams per day for women and more than 20 grams per day for men). Pregnant and lactating women and Married women who are in childbearing age and do not use reliable contraception method. Weight below 50 kg Uncontrolled underlying diseases such as high blood pressure and .... Consumers of Lithium, digoxin, corticosteroids such as prednisone, niacin / nicotinic acid, metronidazole, disulfiram, tetracycline and fluoroquinolone antibiotics (such as ciprofloxacin), hypoglycemic drugs, antiplatelet drugs, diuretics, Antacids such as famotidine and s omeprazole. Consumers of s bloodroot, cat’s claw, chamomile, chaparral, chasteberry, damiana, Echinacea angustifolia, goldenseal, grapefruit juice, licorice, oregano, redclover,St.John’swort, wildcherry, andyucca.
Age
From 18 years old to 65 years old
Gender
Both
Phase
3
Groups that have been masked
  • Participant
  • Care provider
  • Outcome assessor
  • Data analyser
Sample size
Target sample size: 80
Randomization (investigator's opinion)
Randomized
Randomization description
The patients will be assigned to two groups of intervention and control by block randomization. For this purpose blocks of size 4 will be used. Six blocks will include BAAB, ABBA, BABA, BBAA, ABAB, AABB. A number from 1 to 6 is given to each of the mentioned blocks and then a random sequence of twenty is generated from 1 to 6 with Exell program and generate random numbers option. Afterward according to the relevant block, the treatment is assigned to the groups randomly. To hide the random allocation, the numbered dark envelopes will be used, in which the group name is specified in the random sequence generated. Then, according to the order of entering samples, for the first patient the envelope number one is opened and the group will be identified until the end.
Blinding (investigator's opinion)
Double blinded
Blinding description
This study will be performed in a double-blind manner. Unlabeled drugs in similar packages with a unique code will be prepared and a third person which don't contributed directly in the study, will be given the drugs to patients.In this case, patients will not inform the type of treatment they received. Also, the patient examining physician does not inform the type of received intervention.
Placebo
Used
Assignment
Parallel
Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee
Name of ethics committee
Ethics Committee of Qom University of Medical Sciences
Street address
No. 83, 4th alley, 1.1 alley, Safashahr Blvd
City
Qom
Province
Ghoum
Postal code
3716987366
Approval date
2020-07-21, 1399/04/31
Ethics committee reference number
IR.MUQ.REC.1399.148

Health conditions studied

1

Description of health condition studied
Covid-19 infectious disease
ICD-10 code
U07.1
ICD-10 code description
Coronavirus infection :COVID-19, virus identified (a disease diagnosis of COVID-19 confirmed by laboratory testing)

Primary outcomes

1

Description
C-Reactive Protein
Timepoint
Measurement of C-Reactive Protein at the beginning of the study (before the start of the study) and 40 days after the start of dandelion capsule
Method of measurement
Blood test

2

Description
white blood cell
Timepoint
Measurement of white blood cell at the beginning of the study (before the start of the study) and 40 days after the start of dandelion capsule
Method of measurement
Blood test

3

Description
Red blood cell
Timepoint
Measurement of Red blood cell at the beginning of the study (before the start of the study) and 40 days after the start of dandelion capsule
Method of measurement
Blood Test

4

Description
Hemoglobin
Timepoint
Measurement of hemoglobin at the beginning of the study (before the start of the study) and 40 days after the start of dandelion capsule
Method of measurement
Blood test

5

Description
Albumin
Timepoint
Measurement of Albumin at the beginning of the study (before the start of the study) and 40 days after the start of dandelion capsule
Method of measurement
Blood Test

6

Description
Alanine aminotransferase
Timepoint
Measurement of Alanine aminotransferase at the beginning of the study (before the start of the study) and 40 days after the start of dandelion capsule
Method of measurement
Blood Test

7

Description
Aspartate transaminase
Timepoint
Measurement of Aspartate transaminase at the beginning of the study (before the start of the study) and 40 days after the start of dandelion capsule
Method of measurement
Blood Test

8

Description
Creatinine
Timepoint
Measurement of Creatinine at the beginning of the study (before the start of the study) and 40 days after the start of dandelion capsule
Method of measurement
Blood Test

9

Description
Blood Urea Nitrogen
Timepoint
Measurement of Blood Urea Nitrogen at the beginning of the study (before the start of the study) and 40 days after the start of dandelion capsule
Method of measurement
Blood Test

10

Description
Total Bilirubin
Timepoint
Measurement of Total Bilirubin at the beginning of the study (before the start of the study) and 40 days after the start of dandelion capsule
Method of measurement
Blood Test

11

Description
Direct Bilirubin
Timepoint
Measurement of Direct Bilirubin at the beginning of the study (before the start of the study) and 40 days after the start of dandelion capsule
Method of measurement
Blood Test

12

Description
Alkaline Phosphatase
Timepoint
Measurement of Alkaline Phosphatase at the beginning of the study (before the start of the study) and 40 days after the start of dandelion capsule
Method of measurement
Blood Test

13

Description
Blood oxygen saturation
Timepoint
Measurement of Blood oxygen saturation at the beginning of the study (before the start of the study) and 40 days after the start of dandelion capsule
Method of measurement
Pulse Oximeter

14

Description
CT scan of the lungs
Timepoint
Measurement of CT scan of the lungs at the beginning of the study (before the start of the study) and 40 days after the start of dandelion capsule
Method of measurement
CT scan

Secondary outcomes

1

Description
high sensitivity C-Reactive Protein
Timepoint
Before and after medication with Dandelion cap
Method of measurement
Blood Test

Intervention groups

1

Description
Intervention group: Oral yellow herbal Dandelion Capsule 300 mg with production license by the Managing Director of Nik Daroie Shafasaz Amiran Company and produced in Booali Daro Pharmaceutical Factory of Qom, 900 mg (3 capsules) per day after meals and for 40 days will be consumed by the candidates. It should be noted that hospitalized patients with positive COVID-19 test, also receive standard COVID-19 treatments, including interferon beta-1b, dexamethasone, and remdesivir.
Category
Treatment - Drugs

2

Description
Control group: Oral herbal Placebo Dandelion Capsule 300 mg contain starch and similar to dandelion cap (yellow) produced in Booali Daro Pharmaceutical Factory of Qom, 900 mg (3 capsules) per day after meals and for 40 days will be consumed by the candidates. It should be noted that hospitalized patients with positive COVID-19 test, also receive standard COVID-19 treatments, including interferon beta-1b, dexamethasone, and remdesivir.
Category
Placebo

Recruitment centers

1

Recruitment center
Name of recruitment center
Shaheed Beheshti Medical Education Center
Full name of responsible person
Hoda Abolhasani
Street address
Emam street- Shaheed Beheshti Medical Education Center
City
Qom
Province
Ghoum
Postal code
3719964797
Phone
+98 25 3612 2000
Fax
+98 25 3612 2855
Email
hodaabolhasani@gmail.com

Sponsors / Funding sources

1

Sponsor
Name of organization / entity
Ghoum University of Medical Sciences
Full name of responsible person
Ehsan Sharifipour
Street address
No. 83, Alley 4, Alley 1/1, Safashahr St.
City
Qom
Province
Ghoum
Postal code
3716987366
Phone
+98 25 3285 4311
Fax
+98 25 3285 8464
Email
Sharifipour.e@gmail.com
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Ghoum University of Medical Sciences
Proportion provided by this source
100
Public or private sector
Public
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Academic

Person responsible for general inquiries

Contact
Name of organization / entity
Ghoum University of Medical Sciences
Full name of responsible person
Reihaneh Tabaraie
Position
Assistance professor
Latest degree
Specialist
Other areas of specialty/work
Internal Medicine
Street address
Shaheed Beheshti Blvd
City
Qom
Province
Ghoum
Postal code
3719964797
Phone
+98 25 3612 2000
Fax
+98 25 3612 2855
Email
rt1356@yahoo.com
Web page address
http://rt1356@icloud.com

Person responsible for scientific inquiries

Contact
Name of organization / entity
Ghoum University of Medical Sciences
Full name of responsible person
hoda Abolhasani
Position
Assistance professor
Latest degree
Ph.D.
Other areas of specialty/work
Medical Pharmacy
Street address
Pharmacology group, medicin faculty, Qom pardis university of medical sciences
City
Qom
Province
Ghoum
Postal code
3716987366
Phone
+98 25 3320 9071
Fax
+98 25 3320 9071
Email
hodaabolhasani@gmail.com
Web page address
http://ndsaco.com

Person responsible for updating data

Contact
Name of organization / entity
Ghoum University of Medical Sciences
Full name of responsible person
Hoda Abolhasani
Position
Assistance professor
Latest degree
Ph.D.
Other areas of specialty/work
Medical Pharmacy
Street address
Pardis Qom university of medical scienses
City
Qom
Province
Ghoum
Postal code
3716987366
Phone
+98 25 3320 9071
Fax
+98 25 3770 6470
Email
hodaabolhasani@gmail.com
Web page address
http://ndsaco.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)
Yes - There is a plan to make this available
Study Protocol
Yes - There is a plan to make this available
Statistical Analysis Plan
Yes - There is a plan to make this available
Informed Consent Form
Yes - There is a plan to make this available
Clinical Study Report
Yes - There is a plan to make this available
Analytic Code
Not applicable
Data Dictionary
Not applicable
Title and more details about the data/document
After receiving the results of the study, there are plans to publish the article in valid journals
When the data will become available and for how long
all the time
To whom data/document is available
Depending on the journal in which the study is published
Under which criteria data/document could be used
After receiving the results of the study, there are plans to publish the article in valid journals
From where data/document is obtainable
Depending on the journal in which the study is published
What processes are involved for a request to access data/document
Depending on the journal in which the study is published
Comments
Depending on the journal in which the study is published
Loading...